Literature DB >> 16123520

Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?

Adriana Franzese, Maria Immacolata Spagnuolo, Angela Sepe, Giuliana Valerio, Enza Mozzillo, Valeria Raia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123520     DOI: 10.2337/diacare.28.9.2333

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

1.  Oral glucose tolerance testing in children with cystic fibrosis.

Authors:  Katie Larson Ode; Brigitte Frohnert; Theresa Laguna; James Phillips; Bonnie Holme; Warren Regelmann; William Thomas; Antoinette Moran
Journal:  Pediatr Diabetes       Date:  2010-11       Impact factor: 4.866

Review 2.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

3.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Authors:  Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

4.  Drug treatments for managing cystic fibrosis-related diabetes.

Authors:  Gary M Onady; Adrienne Stolfi
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

5.  Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.

Authors:  Francesco Maria Rosanio; Enza Mozzillo; Chiara Cimbalo; Alberto Casertano; Angela Sepe; Valeria Raia; Adriana Franzese; Antonella Tosco
Journal:  Ital J Pediatr       Date:  2021-06-02       Impact factor: 2.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.